Category: 3. Business

  • JPMorgan Raises PT on Micron (MU), Keeps an Overweight Rating

    JPMorgan Raises PT on Micron (MU), Keeps an Overweight Rating

    Micron Technology, Inc. (NASDAQ:MU) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 12, JPMorgan raised the firm’s price target on Micron Technology, Inc. (NASDAQ:MU) from $165 to $185, while keeping an Overweight rating on the stock.

    The improved price target follows the company’s updated fiscal fourth quarter 2025 guidance. Micron Technology, Inc. (NASDAQ:MU) had previously projected fourth quarter guidance expecting revenue of $10.7 billion ± $300 million, non-GAAP gross margins between the range of 41% to 43%. However, on August 11, the company updated this guidance and now expects fourth quarter revenue to reach $11.2 billion ± $100 million, with non-GAAP margins in the range of 44% to 44.5%. Management noted that this improved guidance reflects better pricing of DRAM and strong execution.

    JPMorgan Raises PT on Micron (MU), Keeps an Overweight Rating

    A close-up view of a computer motherboard with integrated semiconductor chips.

    Micron Technology, Inc. (NASDAQ:MU) designs and manufactures high-performance memory and storage products, including DRAM, NAND, and NOR technologies.

    While we acknowledge the potential of MU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • Accenture (ACN) To Acquire an Australian Cybersecurity Firm, CyberCX

    Accenture (ACN) To Acquire an Australian Cybersecurity Firm, CyberCX

    Accenture plc (NYSE:ACN) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Reuters reported that Accenture plc (NYSE:ACN) will buy CyberCX, an Australian cybersecurity firm. The Australian Financial Review valued the deal at over A$1 billion.

    This move comes after a series of major cyberattacks in Australia. Optus faced a huge data breach affecting 10 million users in 2022. Moreover,  Medibank and Qantas also suffered attacks, exposing the customer information of millions of their users. CyberCX was created in 2019 after merging 12 smaller companies and has around 1400 employees in Australia, New Zealand, London, and New York.

    Accenture (ACN) To Acquire an Australian Cybersecurity Firm, CyberCX

    A team of data experts gathered around a computer monitor analyzing customer data.

    Accenture plc (NYSE:ACN) is a services company that helps businesses with strategy, consulting, technology, and operations.

    While we acknowledge the potential of ACN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • UBS Raises Price Target for Berkshire Hathaway (BRK-B), Keeps Buy Rating

    UBS Raises Price Target for Berkshire Hathaway (BRK-B), Keeps Buy Rating

    Berkshire Hathaway Inc. (NYSE:BRK-B) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 4, UBS increased its price target on Berkshire Hathaway Inc. (NYSE:BRK-B) from $595 to $597 and kept its Buy rating.

    This decision came after Berkshire Hathaway Inc. (NYSE:BRK-B) reported operating results for the second quarter of 2025.

    UBS Raises Price Target for Berkshire Hathaway (BRK-B), Keeps Buy Rating

    Skyscrapers with background of graphs and arrows

    The firm’s analyst noted that GEICO, Berkshire Hathaway Inc.’s (NYSE:BRK-B) auto insurance subsidiary, continues to grow and maintain very attractive underlying margins.

    However, UBS pointed out that there is uncertainty about tariffs and the “Big Beautiful Bill,” which could affect federal energy tax policies and the tax rate for Berkshire Hathaway Energy Company.

    Berkshire Hathaway Inc. (NYSE:BRK-B) is an American multinational company led by Warren Buffett. The company and its subsidiaries engage in a wide variety of business activities including insurance and reinsurance, utilities and energy, freight rail transportation, manufacturing, services, and retailing.

    While we acknowledge the potential of BRK-B as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 14 Best Aggressive Growth Stocks to Buy According to Analysts.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • Novo Nordisk (NVO) Receives FDA Approval for Wegovy

    Novo Nordisk (NVO) Receives FDA Approval for Wegovy

    Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis. The drug also moderates advanced liver fibrosis.

    The approval follows positive results from the ESSENCE trial, where the drug depicted better results compared to the placebo. At week 72, 36.8% of patients taking Wegovy improved their liver fibrosis without worsening steatohepatitis. Whereas the placebo only improved results in 22.4% of the patients. With the approval, Wegovy is now the first and only GLP-1 drug approved for noncirrhotic metabolic dysfunction-associated steatohepatitis.

    Novo Nordisk (NVO) Receives FDA Approval for Wegovy

    An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.

    Novo Nordisk (NYSE:NVO) is a global healthcare company specializing in diabetes and obesity care.

    While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • US spy chief Gabbard says UK agreed to drop 'backdoor' mandate for Apple – Reuters

    1. US spy chief Gabbard says UK agreed to drop ‘backdoor’ mandate for Apple  Reuters
    2. UK has ‘agreed to drop’ demand for access to Apple user data, says US  Financial Times
    3. US spy chief Gabbard says UK agreed to drop ‘backdoor’ mandate for Apple  Free Malaysia Today
    4. Inside Apple’s legal black box  Financial Times

    Continue Reading

  • Intel gets $2 billion lifeline in the form of SoftBank equity investment – Reuters

    1. Intel gets $2 billion lifeline in the form of SoftBank equity investment  Reuters
    2. Intel shares jump as Softbank to buy $2bn stake in chip giant  BBC
    3. SoftBank Group and Intel (INTC.O) Sign $2 Billion Investment Agreement  Bitget
    4. SoftBank to invest $2 billion in Intel to become a top-10 shareholder  Reuters
    5. Intel Secures $2B Investment from SoftBank to Accelerate AI and Technology Leadership  The Fast Mode

    Continue Reading

  • Intel’s stock rallies after $2 billion investment by Japan’s SoftBank

    Intel’s stock rallies after $2 billion investment by Japan’s SoftBank

    By Mike Murphy

    Intel headquarters in Santa Clara, Calif.

    Intel Corp. shares jumped in after-hours trading Monday after the chipmaker announced a $2 billion investment by Japan’s SoftBank Group Corp.

    Earlier in the day, Bloomberg News had reported the Trump administration was in talks to take a 10% stake in Intel, essentially equal to the amount of funding the company received from the Chips and Science Act under the Biden administration. That sent the stock down 3.7% in regular trading.

    But shares turned around in the extended session after the SoftBank announcement, rallying 5.4%.

    In a statement late Monday, Intel (INTC) said the deal with SoftBank (JP:9984) comes as both companies “deepen their commitment to investing in advanced technology and semiconductor innovation” in the U.S.

    “Semiconductors are the foundation of every industry,” SoftBank Chief Executive and Chairman Masayoshi Son said in a statement. “For more than 50 years, Intel has been a trusted leader in innovation. This strategic investment reflects our belief that advanced semiconductor manufacturing and supply will further expand in the United States, with Intel playing a critical role.”

    SoftBank shares fell 1.8% in Tokyo trading.

    Intel has been undergoing a painful restructuring as it tries to catch up in the AI chip game, after being surpassed by rivals such Taiwan Semiconductor Manufacturing Corp. (TSM). Intel reported another quarterly loss last month, and President Donald Trump recently called for CEO Lip-Bu Tan’s resignation, though Trump toned down his rhetoric following a meeting with Tan last week.

    Read more: Trump’s clash with Intel’s CEO isn’t just politics – it’s a crucial test for U.S. chip making

    In a statement Monday, Tan said he was “pleased” with SoftBank’s investment, “and I appreciate the confidence [Son] has placed in Intel.”

    SoftBank will pay $23 per share of Intel common stock.

    Intel shares closed Monday at $23.66 a share, and are up about 18% year to date, compared to the S&P 500’s SPX nearly 10% gain.

    Also read: Opinion: Intel has 18 months to determine its future – or Qualcomm and Arm will

    -Mike Murphy

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. 

    
  (END) Dow Jones Newswires
    

    
  08-18-25 2241ET
    

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Singapore Dollar Consolidates Amid Focus on Possible Russia-Ukraine Meeting – The Wall Street Journal

    1. Singapore Dollar Consolidates Amid Focus on Possible Russia-Ukraine Meeting  The Wall Street Journal
    2. Emerging-Market Assets Inch Higher Before Ukraine, Fed Meetings  Bloomberg.com
    3. S&P 500 futures ease ahead of White House talks on Ukraine  MarketWatch
    4. investingLive Asia-pacific FX news wrap 18 Aug: BTC back below 116K  investingLive

    Continue Reading

  • Market exchange rates in China — Aug. 19-Xinhua

    BEIJING, Aug. 19 (Xinhua) — The following are the central parity rates of the Chinese currency renminbi, or the yuan, against 25 major currencies announced on Tuesday by the China Foreign Exchange Trade System:

    Currency Unit Central parity rate in yuan

    U.S. dollar 100 713.59

    Euro 100 834.27

    Japanese yen 100 4.8391

    Hong Kong dollar 100 91.247

    British pound 100 966.20

    Australian dollar 100 464.62

    New Zealand dollar 100 424.26

    Singapore dollar 100 556.92

    Swiss franc 100 885.61

    Canadian dollar 100 518.35

    Pataca 112.94 100

    Malaysian ringgit 59.042 100

    Ruble 1,119.50 100

    Rand 246.58 100

    Korean won 19,379 100

    UAE dirham 51.322 100

    Saudi riyal 52.433 100

    Hungarian forint 4,732.69 100

    Polish zloty 50.922 100

    Danish krone 89.47 100

    Swedish krona 133.60 100

    Norwegian krone 142.49 100

    Turkish lira 571.028 100

    Mexican peso 262.73 100

    Thai baht 453.51 100

    The central parity rate of the yuan against the U.S. dollar is based on a weighted average of prices offered by market makers before the opening of the interbank market each business day.

    The central parity rate of the yuan against the Hong Kong dollar is based on the central parity rate of the yuan against the U.S. dollar and the exchange rate of the Hong Kong dollar against the U.S. dollar at 9 a.m. in international foreign exchange markets on the same business day.

    The central parity rate of the yuan against the Pataca is based on the central parity rate of the yuan against the Hong Kong dollar and the exchange rate of the Pataca against the Hong Kong dollar at 9 a.m. in international foreign exchange markets on the same business day.

    The central parity rates of the yuan against the other 22 currencies are based on the average prices offered by market makers before the opening of the interbank foreign exchange market. ■

    Continue Reading

  • AMRO’s 2025 Annual Consultation Report on Hong Kong, China – ASEAN+3 Macroeconomic Research Office

    AMRO’s 2025 Annual Consultation Report on Hong Kong, China – ASEAN+3 Macroeconomic Research Office

    Hong Kong, China’s economy is navigating a delicate balance of risks and opportunities amid global trade tensions. The most immediate and pressing challenge arises from its sensitivity to global trade, particularly the tensions between the US and China and the associated slowdown in global trade. However, within this volatile environment, Hong Kong’s unique role as a “super connector” between Mainland China and the rest of the world has come into sharper focus, bolstering financial activities and offering potential opportunities amid uncertainties.

    To fortify its economic recovery in the face of compounded external and domestic risks, it will be critical to deploy a coordinated and multi-faceted policy response comprising timely and targeted policy support, market diversification, and efforts to cultivate new growth drivers.


    Continue Reading